Severity of AD increases resource use and costs in France

Severity of AD increases resource use and costs in France PharmacoEconomics & Outcomes News 792, p27 - 2 Dec 2017 Severity of AD increases resource use and costs in France Increased severity of Alzheimer’s disease (AD) appears to increase resource use and societal costs in France, according to findings of the Eli Lilly and Co- funded study published in Value in Health. This analysis of data from the French cohort of the observational GERAS study investigated resource use and societal costs over 18 months in 419 community- dwelling patients with AD, and the effects of cognitive decline on patient costs and societal costs. Patients were enrolled between October 2010 and September 2011. Cumulative total societal costs over the 18-month period were significantly higher in patients with moderately severe or severe AD than in those with mild or moderate AD (€44 171 vs €24 140 and €34 287, respectively; p<0.001). Caregiver informal care accounted for 51%–53% of total societal costs, ranging from €12 556 in patients with mild AD to €22 704 in those with moderately severe or severe AD. Cognitive decline (defined as institutionalisation or reduction in Mini-Mental State Examination score of ≥3 points) was associated with a 12.5% increase in costs (p=0.02). While caregiver time differed significantly between AD severity groups (p<0.001), caregiver time per month increased in all severity groups at 6, 12 and 18 months. "Increasing severity of AD dementia in France is associated with increased total societal and patient costs, and clinically meaningful cognitive decline is associated with increased costs," concluded the authors. "This study confirms the quantity and importance of the caregiver burden and costs associated with AD . . . Health and social policies should further focus on supporting the caregiver," they said. * 2010 euros Rapp T, et al. Resource Use and Cost of Alzheimer’s Disease in France: 18-Month Results from the GERAS Observational Study. Value in Health : 11 Nov 2017. Available from: URL: https://doi.org/10.1016/j.jval.2017.09.019 803286172 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Severity of AD increases resource use and costs in France

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/severity-of-ad-increases-resource-use-and-costs-in-france-OibQ1S2WUj
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4550-2
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p27 - 2 Dec 2017 Severity of AD increases resource use and costs in France Increased severity of Alzheimer’s disease (AD) appears to increase resource use and societal costs in France, according to findings of the Eli Lilly and Co- funded study published in Value in Health. This analysis of data from the French cohort of the observational GERAS study investigated resource use and societal costs over 18 months in 419 community- dwelling patients with AD, and the effects of cognitive decline on patient costs and societal costs. Patients were enrolled between October 2010 and September 2011. Cumulative total societal costs over the 18-month period were significantly higher in patients with moderately severe or severe AD than in those with mild or moderate AD (€44 171 vs €24 140 and €34 287, respectively; p<0.001). Caregiver informal care accounted for 51%–53% of total societal costs, ranging from €12 556 in patients with mild AD to €22 704 in those with moderately severe or severe AD. Cognitive decline (defined as institutionalisation or reduction in Mini-Mental State Examination score of ≥3 points) was associated with a 12.5% increase in costs (p=0.02). While caregiver time differed significantly between AD severity groups (p<0.001), caregiver time per month increased in all severity groups at 6, 12 and 18 months. "Increasing severity of AD dementia in France is associated with increased total societal and patient costs, and clinically meaningful cognitive decline is associated with increased costs," concluded the authors. "This study confirms the quantity and importance of the caregiver burden and costs associated with AD . . . Health and social policies should further focus on supporting the caregiver," they said. * 2010 euros Rapp T, et al. Resource Use and Cost of Alzheimer’s Disease in France: 18-Month Results from the GERAS Observational Study. Value in Health : 11 Nov 2017. Available from: URL: https://doi.org/10.1016/j.jval.2017.09.019 803286172 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off